This study extensively examined the role of a 5-HT 1A receptor in controlling voiding 36 function in anesthetized male rats. A simultaneous recording of the intravesical pressure (IVP), 37 external urethral sphincter (EUS)-electromyography (EMG), and urine flow rate (UFR) 38 during continuous cystometry was utilized. 8-Hydroxy-2-(di-n-propylamino)-tetralin (8-OH-39 DPAT), a 5-HT 1A receptor agonist, significantly improved the voiding efficiency (VE) as 40 detected by increases in the evoked contraction amplitude, EUS burst period, and silent period, 41 and decreases in the volume threshold, pressure threshold, and residual volume. Interestingly, 42 the UFR during voiding was reduced by 8-OH-DPAT, as evidenced by decreases in the 43 maximal UFR and mean UFRs of the voiding period, spike duration, and inter-spike interval. 44
INTRODUCTION 58
Serotonin (5-hydroxytryptamine, 5-HT) comprises 14 structurally different 5-HT receptors 59 in mammalian species, including seven subfamilies (5-HT 1 to 5-HT 7 ) (28). A number of 5-HT 60 receptor subfamilies, particularly 5-HT 1A receptors, located at nerve terminals are involved in 61
Physiological investigations 109
Rats underwent simultaneous recordings of IVP, EUS-EMG, and UFR during continuous 110 transvesical cystometry that usually began 3~4 h after induction of anesthesia. After manually 111 emptying the bladder, transvesical cystometry was performed at an infusion rate of 0.12 ml/min 112 with physiological saline at room temperature (5, 26). The urethra was open allowing 113 elimination of fluid during micturition. The infusion pump was turned off after two or three 114 voiding contractions. All recorded data were first amplified and sampled at 10 kHz (Biopac MP 115 150, BIOPAC Systems, CA, USA), and the recorded EUS-EMG was further filtered by a 116 3~3000-Hz band-pass filter. 117
Researchers who analyzed the IVP, EUS-EMG, and UFR were blinded to the status of the 118 rats. Various IVP parameters were measured as previously reported (5, 23, 26) : 1) the volume 119 threshold, the minimum infused volume of saline sufficient to induce the first 120 voiding contraction; 2) pressure threshold, the pressure required to induce voiding contractions; 121 3) contraction amplitude, the maximal pressure during voiding; 4) evoked contraction amplitude, 122 the contraction amplitude minus the pressure threshold; 5) bladder compliance, the ratio of the 123 volume threshold to the pressure threshold; 6) residual volume, the volume of saline withdrawn 124 through the intravesical catheter after voiding; 7) voided volume, the micturition volume 125 threshold minus the residual volume; and 8) voiding efficiency, the ratio of the voided volume 126 to the micturition volume threshold. In addition, as described in earlier papers (5, 25), three 127 EUS-EMG parameters were determined including the burst period, silent period, and active 128 period, as shown in Fig 1.  129 To analyze the UFR, several parameters were measured: 1) the maximal UFR, the 130 maximal value of the UFR during the voiding period (Fig. 1) ; 2) mean UFR of the voiding 131 period; 3) spike duration, the duration of a spike; 4) inter-spike interval, the interval between 132 two successive spikes; 5) mean UFR of the spike duration, the average value of the UFR of all 133 spike durations; and 6) mean UFR of the inter-spike interval, the average value of all inter-spike 134 intervals. 135
Drug administration 136
8-OH-DAPT and WAY-100635 (both from Sigma, St. Louis, MO, USA) were dissolved in 137 saline. To assess the roles of 5-HT 1A receptors in voiding function, 8-OH-DAPT (0.3 mg/kg, 138 i.v.) and WAY-100635 (0.1 mg/kg, i.v.) were administrated to rats at intervals of no less than 1 139 h. The drug dose was in accordance with dosages determined in previous studies (8, 10, 22) . 140
The first post-treatment urodynamic examinations were completed within 20~45 min following 141 drug administration because of the short half-life of 8-OH-DAPT (14, 22) . To further determine 142 the independent effect of 8-OH-DPAT or WAY-100635 on urethral smooth muscle activity, 143 some rats received an intravenous injection of α-bungarotoxin (0.4 mg/kg, dissolved in saline) 144 30~40 min prior to WAY-100635 treatment. Subsequently, those rats were further treated with 145 8-OH-DPAT, at approximately 2~3 h after α-bungarotoxin administration. The effects of α-146 bungarotoxin generally last for 3~6 h (21). The IVP, EUS-EMG, and UFR were simultaneously 147 recorded both before and after administration of these drugs. 148
Statistical analysis 149
This study presents all data as means ± SD. One-way ANOVA was used to compare 150 parameters obtained from the IVP, EUS-EMG, and UFR recordings. ANOVA was followed by 151
Tukey HSD post-hoc paired comparisons (SigmaStat, SPSS, Chicago, IL, USA), and a value of 152 P < 0.05 was considered significant in all analyses. In addition, a Pearson correlation test was 153 used to analyze the timing relationship between recordings. 154
155

RESULTS
156
Typical patterns of the IVP, EUS-EMG, and UFR 157
Typical IVP, EUS-EMG, and UFR recordings during the continuous transvesical infusion 158 of saline in urethane-anesthetized male rats are depicted in Fig. 1A . When the volume 159 threshold was reached, the bladder contracted and voiding occurred. Subsequent contractions 160 occurred at earlier times during filling than the first contraction, because the residual volume 161 after the first contraction was added to the infused volume. The EUS exhibited low-amplitude 162 tonic activity during the initial filling phase and between micturition contractions; meanwhile 163 no urine flow was detected in the UFR measurement. However, during bladder contractions, 164 EUS activity markedly increased in amplitude, which coincided with the occurrence of a urine 165 flow event.
Detailed features of EUS-EMG activity during a single 166 micturition contraction clearly presented a long burst period, as shown in Fig. 1B . Burst 167 discharges in the burst period showed clusters of high-frequency EMG activity (corresponding 168 to an active period) separated by periods of quiescence (corresponding to a silent period), as 169 shown in Fig. 1C . In addition, the EUS burst period was accompanied by IVP and UFR which 170
were both superimposed upon a series of high-frequency oscillations (Fig. 1B, C) . Relationships 171 among the IVP, EUS, and UFR recordings during the burst period were modeled by four critical 172 IVP points, and the oscillatory IVP was classified into two waveform templates (i.e., small and 173 large waves), as shown in Fig. 2B . Small IVP waves typically appeared at point (a) and lasted to 174 point (c); subsequently, a large wave continued at point (c) and ended at point (a'). At the peak 175 of the small wave (point (b)), the EUS-EMG indicated the occurrence of an active period 176 (correlation value R = 0.87, obtained from 12 rats); and this active period usually ceased at the 177 end of the small wave (point (c); R = 0.84). The oscillatory UFR was only composed of a single 178 waveform template, which was divided into spike durations and inter-spike intervals (Fig. 1C) . 179
The ascending periods of the spike duration rhythmically coincided with the appearance of the 180 EUS active period, and correlation values of the initial and end points of this ascending period 181 to IVP points (b) and (c) were 0.91 and 0.89, respectively. Subsequently, the descending period 182 of spikes was generally distributed within the EUS silent period. The peak of spike durations 183 usually coincided with the endpoint of the active period, and a high correlation between the 184 peak and IVP point (c) was detected (R = 0.92). 185
Effects of 8-OH-DPAT and WAY-100635 on the IVP 186
Effects of the intravenous administration of 8-OH-DPAT (0.3 mg/kg i.v.) and WAY-100635 187 (0.1 mg/kg i.v.) on control of the IVP, EUS-EMG, and UFR activity were examined in 188 anesthetized male rats (n = 12). Table 1 summarizes all IVP parameters obtained from rats  189 before and after 5-HT drug treatment. 8-OH-DPAT significantly reduced the volume 190 threshold and pressure threshold for inducing a reflex bladder contraction, while it significantly 191 increased the evoked contraction amplitude ( Fig. 3 ; Table 1 ). In addition, compliance of the 192 bladder contraction, i.e., the ratio of the volume threshold to the pressure threshold, was 193 significantly decreased by the drug, indicating an enhancement of bladder micturition reflexes. 194
These results suggest that the 5-HT 1A receptor agonist markedly facilitated bladder emptying, 195 and the voiding efficiency was subsequently improved from 69.4% to 85.8% (P < 0.05; Table  196 1). Conversely, treatment of rats with WAY-100635, a 5-HT 1A receptor antagonist, 197 produced effects opposite to those produced by 8-OH-DPAT ( Fig. 3 ; Table 1 ). The voiding 198 efficiency was significantly reduced from 69.4% to 35.1% (P < 0.05). 199
Effects of 8-OH-DPAT and WAY-100635 on the EUS-EMG 200
The EUS exhibited low-amplitude tonic activity during the initial filling phase 201 and between micturition contractions, while large amplitudes were detected by the EUS-EMG 202 during the bladder voiding phase (Fig. 3A) . Although the general pattern of the EUS-EMG 203 during continuous cystometry was similar in rats before and after 8-OH-DPAT or WAY-204 100635 treatment (Fig. 3) , there were marked quantifiable differences during the voiding phase. 205 Table 2 summarizes EUS-EMG measurements in rats before and after 8-OH-DPAT or WAY-206 100635 treatment. Compared to control data, 8-OH-DPAT significantly increased the duration 207 of the burst period, whereas it was markedly reduced by WAY-100635 ( Fig. 4 ; Table 2 ). 208
Similarly, 8-OH-DPAT and WAY-100635 treatment dramatically prolonged and shortened the 209 silent period, respectively (middle traces in Fig. 5 ; Table 2 ). However, the active period was not 210 significantly affected by WAY-100635 or 8-OH-DPAT treatment in rats. 211
Effects of 8-OH-DPAT and WAY-100635 on the UFR 212
Cystometric results showed that the appearance of UFR events in rats after 8-OH-DPAT or 213 WAY-100635 treatment remained synchronized with the occurrence of the EUS burst period, as 214
shown in bottom traces in Figs. 3 and 4. Several UFR parameters were obtained from rats both 215 before and after 5-HT drug treatment, as tabulated in Table 3 . Experimental results showed that 216 the maximal UFR and mean UFRs of the voiding period, spike duration, and inter-spike interval 217
were all decreased by 8-OH-DPAT, which implied that the UFR was as a whole reduced by 218 the 5-HT 1A receptor agonist. However, the total length of oscillatory flow was markedly 219 elongated by the drug, which was approximately the same length as its corresponding EUS 220 burst period (Fig. 4) . Importantly, 8-OH-DPAT significantly reduced the spike duration, 221 whereas the drug significantly increased the inter-spike interval (lower traces in Fig. 5B ; Table  222 3). Conversely, opposite effects were detected in rats after WAY-100635 treatment. 223
Characteristics of micturition contractions during the burst period 224
Relationships among IVP, EUS-EMG, and UFR during the EUS burst period in rats after 5-225 HT drug treatment were examined in detail, as shown in Fig. 5 . Similar to the control IVP, 226 four critical pressure points in the oscillatory pattern of IVP in rats after 8-OH-DPAT were still 227 readily detected, in which the oscillatory IVP was divided into small and large waves. However, 228 WAY-100635 markedly altered the oscillatory pattern to a single-wave pattern (Fig. 5C) , 229 and the four critical IVP points that appeared in the control data were not recognized in any 230 micturition contractions (n = 72 of 72 contractions across 12 rats). The initial point of the EUS 231 active period in the control condition was approximately at the IVP point (b), but this timing 232 relationship was altered in rats after 8-OH-DPAT, in that point (b) was detected earlier than the 233 appearance of the active period (n = 72 of 72 voiding reflexes across 12 rats; Fig. 5B ). 234 Interestingly, the spike duration was longer than its inter-spike interval in the control condition, 235 whereas, after 8-OH-DPAT treatment, the inter-spike duration became longer than its spike 236 duration (Table 3 ; Fig. 5 ). 237
Effects of 5-HT drug treatment in rats after neuromuscular blockade 238
Our results demonstrated that the UFR was reduced by 8-OH-DPAT but was elevated by 239 WAY-100635 treatment (Table 3) . To further determine the independent roles of urethral 240 striated and smooth muscles in the UFR and voiding efficiency in rats after 5-HT drug 241 treatment, some rats (n = 6) were treated with α-bungarotoxin. Figure 6 shows examples of the 242 independent effects of WAY-100635 and 8-OH-DPAT during continuous cystometry in rats 243 after α-bungarotoxin treatment. After neuromuscular blockade treatment, spontaneous reflex 244 bladder contractions still appeared during transvesical cystometry, but EUS-EMG and UFR 245 activities were both nearly completely eliminated (Fig. 6B ). The voiding efficiency in rats after 246 α-bungarotoxin treatment was reduced from 70.1 ± 7.2% to 0.7 ± 0.5% (P < 0.05). 247
Subsequently, WAY-100635 was administrated to rats 30~40 min after α-bungarotoxin 248 treatment. The drug significantly increased the volume threshold for inducing reflex 249 bladder contractions, while significant urine flow activity reemerged during reflex 250 bladder contractions, and the voiding efficiency significantly increased to 12.8 ± 7.4% (P < 251 0.05). After the same rat was further treated with 8-OH-DPAT at approximately 2.5 h after α-252 bungarotoxin treatment, reflex bladder contractions still existed, but no significant UFR activity 253 was detected during transvesical cystometry (Fig. 6D) , and the voiding efficiency was again 254 reduced to close to the zero level (0.4 ± 0.3%). 255
This study shows that activation of 5-HT 1A receptors in male rats with 8-OH-DPAT, a 5-257 HT 1A agonist, generally reduced the UFR during micturition contractions, as evidenced by 258 significant decreases in the maximal UFR and mean UFRs of the voiding period, spike duration, 259 and inter-spike interval (Table  3) . However, the voiding efficiency 260 during continuous cystometry was not reduced but was improved by the drug ( Fig. 4 ; Table 1) . 261
Conversely, treatment of rats with WAY-100635, a 5-HT 1A antagonist, produced effects 262 opposite to those produced by 8-OH-DPAT. Although numerous studies (2, 5, 6, 8, 18 ) 263
reported that 8-OH-DPAT significantly improved the voiding function in female rats, to the best 264 of our knowledge, our study is the first to report on the effects of the 5-HT drug on regulating 265 the UFR in male rats. 266
One important question emerging from this study is why 8-OH-DPAT significantly 267 improved the voiding efficiency but the UFR during voiding was substantially reduced rather 268 than increased by the drug. This contradiction can be explained by three possibilities, including 269 1) enhanced bladder reflex activity, 2) facilitated urethral smooth muscle contractions, and 3) 270 altered the pattern of urethral striated muscle activity during the voiding period by 8-OH-DPAT 271 treatment. First, the enhanced voiding efficiency by 8-OH-DPAT was attributed to 272 enhancement of the bladder reflex activity, as evidenced by an increase in the bladder 273 evoked contraction amplitude and a decrease in the volume threshold for induction of 274 bladder contractions by the drug (Table 1 ). The increase in the evoked contraction amplitude 275 represents improvements in the bladder contractile ability for bladder evacuation during voiding. 276
In addition, reduction of the volume threshold might have resulted from the 5-HT 1A receptor 277 agonist facilitating the micturition switching circuit in the pontine micturition center (20, 40) or 278 enhancing bladder afferent input or afferent processing in the spinal cord (3, 22) . In this way, 279 reduction of the volume threshold accompanied by increased bladder contractions by 8-OH-280 DPAT during voiding would largely improve bladder emptying. 281
The urethral smooth muscle activity modulated by 5-HT drug possibly accounts for the 282 reduction in the UFR. According to Poiseuille's law (1), the rate and resistance at which a 283 fluid flows through a pipe are positively and inversely proportional to the pipe diameter 284 raised to the fourth power, respectively. Although the urethra is more complex, as the urethra is 285 not a rigid pipe and has elastic components, the urethral cross-sectional diameter or area 286 remains a critical factor dominating the UFR. Our recent study demonstrated that 8-OH-DPAT 287 significantly elevated the urethral pressure during voiding in male rats after neuromuscular 288 blockade treatment (15), which implies that 8-OH-DPAT may facilitate urethral smooth 289 muscle contractions and decrease the urethral cross-sectional diameter, thereby reducing the 290 UFR during voiding. In addition, in the present study, we further proved that WAY-100635 291 significantly increased the voiding efficiency from 0.7% to 12.8% in rats after α-bungarotoxin 292 treatment, and subsequent 8-OH-DPAT treatment again reduced the voiding efficiency to close 293 to 0% (Fig. 6) . Thus, the combined data suggested that urethral smooth muscle activity plays an 294 important role in regulating the UFR in male rats. 295
On the other hand, alteration of urethral striated muscle activity is another possible 296 explanation of this contradiction. 8-OH-DPAT significantly prolonging the EUS silent 297 period could be another factor reducing the UFR. The EUS burst period, which represents the 298 relaxation and opening of the outlet, is essential to achieve efficient voiding (9, 11) in rats, 299 and particularly urine release is mainly promoted by phasic EUS contractions (active period). In 300 the present study, 8-OH-DPAT markedly prolonged the duration of EUS relaxation (silent 301 period) but did not alter the active period (Table 2) . Therefore, the longer silent 302 period would decrease the average UFR of the burst period. Contrarily, the total EUS burst 303 period was significantly prolonged to approximately 2-fold that of the control by 8-OH-DPAT 304 (Fig. 4, Table 2 ). This long EUS burst period represents a longer duration of voiding for 305 emptying bladder urine, which would largely compensate for the lower UFR caused by urethral 306 smooth muscle contractions and longer silent periods. Taken together, a decreased bladder 307 volume threshold, an enhanced detrusor contractile ability, and a lengthened EUS burst 308 period induced by activation of 5-HT receptors would all contribute to significantly improving 309 the voiding efficiency regardless of the lower UFR during voiding. 310
In the present study, administration of 8-OH-DPAT in male rats significantly reduced the 312 bladder volume threshold, increased the detrusor contractile ability, prolonged the durations of 313 the EUS burst and active periods, and subsequently improved the voiding efficiency, which 314 were all consistent with results in females (2, 5, 8, 18) . EUS burst activity is necessary for 315 efficient bladder emptying in rats; this assertion was demonstrated by the EUS paralysis with α-316 bungarotoxin significantly reducing the voiding efficiency from ~77-65% to ~30-50% in female 317 rats (8, 26) . Interestingly, in the present study, almost no urine was 318 released during continuous cystometry by male rats under a condition of EUS paralysis, and the 319 average voiding efficiency was dramatically reduced from 70.1% to approximately 0% (Fig.  320   6B ). These findings imply that the lack of EUS burst activity seemed to have a larger impact on 321 the voiding efficiency in male rats than that in females. This difference could be attributed to 322 the fact that some sexual differences exist in the urethral anatomy and function (11, 15, 27, 29, 323 41). For example, male rats generally have a longer urethra and thicker EUS overlaying the 324 urethra compared to female rats (11, 27, 29) , and the bladder outlet resistance in male rats is 325 significantly higher than that in female rats (15). With those sexual differences, male rats 326 would be expected to need a higher evacuation energy to produce efficient bladder emptying. 327
It is noteworthy that 8-OH-DPAT significantly elongated the length of the EUS silent 328 period, but the amplitudes or durations of individual oscillatory waves (spike duration) in the 329 UFR did not concomitantly increase (Fig. 5B) . Meanwhile, although the inter-spike interval was 330 simultaneously prolonged during the long EUS active period ( Fig. 5B; Table 3 ), the mean flow 331 rate of this interval was not elevated by the drug, but dropped to close to the zero level, 332 indicating that almost no urine flow occurred during the long inter-spike interval. This 333 phenomenon can be explained by the urethral smooth muscle contraction being activated by 8-334 OH-DPAT, in which the urethral resistance for urine evacuation might have been 335 elevated and thus only induced a short-term duration of urine flow (a short spike duration; 336 Table 3 ). Conversely, WAY-100635 dramatically relaxed the urethral smooth muscle, which 337 was accompanied by a short EUS silent period (Fig. 5C) , and led to a high speed of continuous 338 oscillatory urine flow during EUS burst activity (Fig. 4C) . Thus, all these results 339 demonstrated that, in male rats, the short duration of oscillatory waves (short spike durations) in 340 the UFR was mainly associated with a urethral smooth muscle contraction induced by 8-OH-341
DPAT. 342
For UFR measurements, a discontinuous-like pattern of urine flow was detected, 343 and this characteristic of UFR recordings was similar to that in previous studies by Streng et al. 344 (30, 32, 33) . However, the pattern of EUS-EMG in our study completely differed from that of 345 Streng et al. This is because the approach used for EUS-EMG recording by Streng et al. (30, 32 ) 346 was a monopolar suction electrode method, and that in our study was a bipolar wire electrode 347 method. This discrepancy made it difficult to compare EUS-EMG data of ours and previous 348 studies'. However, the bipolar wire approach when compared to the monopolar 349 approach commonly has a more-restricted recording area and directional sensitivity of the 350 motor unit of action potentials (MUAP) from the background but is more liable to be 351 affected by movement artifact noises and usually requires further processing via a digital filter. 352
In the present study, a 3~3000-Hz band-pass filter was used to reduce artifact noises, which 353
should not have significantly altered the properties of the original EUS-EMG signal. This is 354 because the frequency of the EUS-EMG signal in rats is mainly located at 200~600 Hz (4) Relationships of the IVP and UFR with EUS activity were also examined in rats before 359 and after drug treatment. From our EUS-EMG recordings, the exact timing of the 360 EUS contraction and relaxation was readily distinguished by an active period and a silent period, 361 respectively. Interestingly, the initial point of the EUS active period coincided with the starting 362 point of the UFR spike duration (Fig. 5A) , while the endpoint of the active period was usually 363 located at the peak of the spike duration or the IVP point (c). Note that these timing 364 relationships were not altered by administration of 5-HT receptor agonist or antagonist (Fig. 5B,  365 C), which suggests that phasic EUS contractions are one of the main mechanisms producing the 366 energy (force) that initiates oscillatory urine flow. 367
One limitation of the present study was the use of rats to investigate LUT functions. 368
Although rats are widely used for physiological and pharmacological studies of the LUT (13), 369 rats (and dogs) exhibit phasic patterns of EUS activity during voiding, in contrast to the 370 (complete) relaxation of the sphincter observed in humans (and cats). Phasic EUS activation is 371 essential to efficient voiding in rats (26), as evidenced by the present results of EUS paralysis 372 with α-bungarotoxin significantly reducing the voiding efficiency. However, relaxation of the 373 EUS promotes complete bladder emptying in humans. Therefore, it is not clear whether the 374 present results that 5-HT 1A activation altered the flow rate and voiding efficiency by increasing 375 bladder contractility and smooth-muscle mediated urethral contractions will translate to humans 376 (males), where the neural control of EUS activity differs from that in the rat. 377
Perspectives and significance 378
Serotonin may have different functions in the central nervous control of the LUT due to 379 Species differences. For example, in cats, 5-HT receptor activation by 8-OH-DPAT inhibits 380 bladder activity and facilitates continence EUS activity under conditions of a bladder irritated 381 with acetic acid (37). Contrarily, in rats, the drug has a facilitative effect on bladder activity and 382 promotes emptying EUS activity (5). 383
Several studies indicated that bulbospinal projections from raphe neurons in the brainstem 384 might mediate inhibitory control over voiding function (7, 12, 34) . 5-HT 1A autoreceptors are 385 involved in negative feedback control of 5-HT release from raphe neurons (16, 17, 21) . In rats, 386 administration of WAY-100635 increases the firing rate of raphe neurons by blocking 5-HT 1A 387 inhibitory autoreceptors, and the 5-HT is largely secreted onto 5-HT 2C receptors which activates 388 an inhibitory interneuron to inhibit the parasympathetic drive to the bladder (12, 28) ranged from points (a) to (c), and subsequently the large wave was from points (c) to (a'). At 552 the peak of the small wave (point (b)), the initiation of EUS occurred in an active period (AP) 553 of the EUS-EMG; and the AP ended at point (c). In the meantime, the UFR measurement 554 exhibited a rapidly increasing flow rate during the AP. Note that the peak of the ascending UFR 555 was exactly located at the endpoint of the AP or IVP point (c), and at the IVP point (c), the UFR 556 was immediately transformed into a descending curve that was distributed within the EUS silent 557 period. 558 pressure points in the oscillatory IVP in the rat after 8-OH-DPAT treatment (B) were still 577 readily detected, which was similar to results of the control (A); however, WAY-100635 578 significantly altered the basic pattern of the oscillatory IVP (C), and therefore it was difficult to 579 distinguish the four critical pressure points observed in the control IVP. Note that 8-OH-DPAT 580 also significantly increased the silent period of the EUS-EMG and the inter-spike interval of the 581 UFR, but WAY-100635 produced effects opposite to those produced by 8-OH-DPAT. 582 Values are means ± SD; n = 12 male rats. * Statistically significant difference from the control value, P < 0.05. Bladder compliance is the ratio of the volume threshold to the pressure threshold. Values are means ± SD; n =12 male rats. * Statistically significant difference from the control value, P < 0.05. Silent and active periods denote the average durations of quiescent and tonic EUS-EMG activities during the burst period shown in Fig. 1 . 
8-OH-DPAT
9.84 ± 1.29 * 3.33 ± 0.37 * 6.69 ± 0.78 * 0.07 ± 0.03 * 89.7 ± 5.3 * 102.3 ± 10.8 *
WAY-100635
18.06 ± 1.02 * 9.25 ± 0.58 * 10.74 ± 1.02 * 0.37 ± 0.07 * 112.8 ± 2.9 13.8 ± 1.4 * Values are means ± SD; n = 12 male rats. * Statistically significant difference from the control value, P < 0.05.
